<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C55B67AF-89DB-48EB-B965-863E2F3BA008"><gtr:id>C55B67AF-89DB-48EB-B965-863E2F3BA008</gtr:id><gtr:name>Tottori University</gtr:name><gtr:address><gtr:line1>4-101 Koyama-Minami</gtr:line1><gtr:postCode>680-8550</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FB5D6522-20EB-4EF7-B531-9DACC59C5706"><gtr:id>FB5D6522-20EB-4EF7-B531-9DACC59C5706</gtr:id><gtr:name> University of Pavia</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/091A7281-194A-4C7B-8E9A-0CEB4FEE954B"><gtr:id>091A7281-194A-4C7B-8E9A-0CEB4FEE954B</gtr:id><gtr:name>Faculty of Medicine</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Cell and Developmental Biology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C55B67AF-89DB-48EB-B965-863E2F3BA008"><gtr:id>C55B67AF-89DB-48EB-B965-863E2F3BA008</gtr:id><gtr:name>Tottori University</gtr:name><gtr:address><gtr:line1>4-101 Koyama-Minami</gtr:line1><gtr:postCode>680-8550</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FB5D6522-20EB-4EF7-B531-9DACC59C5706"><gtr:id>FB5D6522-20EB-4EF7-B531-9DACC59C5706</gtr:id><gtr:name> University of Pavia</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/091A7281-194A-4C7B-8E9A-0CEB4FEE954B"><gtr:id>091A7281-194A-4C7B-8E9A-0CEB4FEE954B</gtr:id><gtr:name>Faculty of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C340AF8C-9E82-4A93-8408-6E1E7440CE10"><gtr:id>C340AF8C-9E82-4A93-8408-6E1E7440CE10</gtr:id><gtr:firstName>Francesco Saverio</gtr:firstName><gtr:surname>Tedesco</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AB7FF0AD-CFA3-43D4-AE24-6F42B623F459"><gtr:id>AB7FF0AD-CFA3-43D4-AE24-6F42B623F459</gtr:id><gtr:firstName>Sara</gtr:firstName><gtr:surname>Benedetti</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ECF21117-DCC5-428E-B4D7-38215075B95F"><gtr:id>ECF21117-DCC5-428E-B4D7-38215075B95F</gtr:id><gtr:firstName>Mattia</gtr:firstName><gtr:otherNames>Francesco Maria</gtr:otherNames><gtr:surname>Gerli</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/29AC0930-61EC-433A-875B-3EE13DDED121"><gtr:id>29AC0930-61EC-433A-875B-3EE13DDED121</gtr:id><gtr:firstName>Giulio</gtr:firstName><gtr:surname>Cossu</gtr:surname><gtr:orcidId>0000-0001-5863-9593</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ006785%2F1"><gtr:id>8A9672A1-90D1-4B7A-97FE-3C4775798C05</gtr:id><gtr:title>Engineering human artificial chromosomes containing the dystrophin locus for autologous cell therapy of Duchenne Muscular Dystrophy.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J006785/1</gtr:grantReference><gtr:abstractText>Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy (1/3500 males). It affects skeletal and cardiac muscles, leading to progressive loss of movements, confinement to a wheelchair and finally to total paralysis and assisted ventilation. Death occurs usually in the third decade of life because of cardiac and/or respiratory failure. Improved medical assistance has increased the lifespan of patients but still there is no efficacious therapy and steroids are the only palliative treatment available. Among several novel strategies that are entering clinical experimentation, our group focused on cell therapy, based upon intra-arterial infusion of mesoangioblasts (MABs), stem/progenitor cells associated to blood vessels that showed efficacy in dystrophic mice and dogs. Although a phase I/II clinical trial based upon allogeneic transplantation of mesoangioblasts is currently running, gene therapy of autologous cells would be preferable (no immune suppression and no need of HLA-matched donor) but the large size of the dystrophin gene (2.4Mb) hampers the use of viral vectors. Our group pioneered the use of human artificial chromosomes (HACs) containing the whole dystrophin locus for muscular dystrophy (DYS-HAC), showing efficacy of this strategy in dystrophic mouse cells. Based on the above, we now plan to develop a definitive strategy that would allow translation to human cells and boosting the therapeutic effect.
First, we will insert into the DYS-HAC an &amp;quot;immortalizing cassette&amp;quot; containing genes that allow bypassing senescence (telomerase and Bm1) and a suicide gene as a safety device. Preliminary results confirm that this cassette works in human cells. The cassette is floxed and thus can be excised from the HAC before cells are infused into patients.The DYS-HAC will also contain an inducible MyoD (i.e linked to the Estrogen Receptor: MyoD-ER), a myogenic master gene that will allow induction of muscle differentiation (which is variable among different patients). 
The optimal number of copies of dystrophin to include will be determined to achieve the optimal level of expression for a single genetically corrected nucleus to compensate for the muscle fibre resident nuclei that cannot synthesize it. All the subsequent generations of HACs will be transferred in human dystrophic mesoangioblasts that will be then challenged for their ability to repair dystrophic muscle and ameliorate the disease.
The PI is a leader in the field of cell therapy; his expertise, and that of his colleagues, will guarantee a high probability of success for this ambitious but realistic project, whose results may lead to rapid clinical translation and, at the same time, pave the way for other monogenic diseases, characterized by mutations of a very large gene.</gtr:abstractText><gtr:technicalSummary>The aim of this project is to develop a novel cell therapy for Duchenne Muscular Dystrophy (DMD) based upon transplantation of autologous mesoangioblasts (MABs; vessel associated progenitors) engineered with a human artificial chromosome (HAC) vector containing the entire 2.4 megabases of the human dystrophin locus (DYS-HAC). Specifically we will insert into the DYS-HAC: 
a) Floxed immortalizing sequences (human telomerase reverse transcriptase (hTERT), Bmi-1 and the suicide gene Herpex Simplex Virus Thymidine Kinase (HSV-TK). These will allow us to extend, reversibly, the lifespan of primary human MABs, excision of the floxed cassette by a non-integrating lentiviral vector expressing the Cre recombinase and negative selection of cells where the cassette has not been excised; 
b) An inducible MyoD (MyoD-ER) where the myogenic factor is linked to the Estrogen Receptor, to induce myogenesis at will, since mesoangioblasts vary in their myogenic potency among different patients. 
c) Two or more full-length human dystrophin cDNAs to compensate for gene dosage insufficiency deriving from fusion of relatively few genetically corrected cells in a fiber containing a large majority of genetically defective nuclei. Transfer of different HACs, each with a different selection marker, will allow us to determine the number of copies required for optimal protein production.
Subsequent generations of HACs, progressively incorporating the above mentioned functions, will be built and transferred into MABs from DMD patients. Proliferation, differentiation, transformation/tumorigenicity of cells will be tested in vitro and in vivo (scid/mdx dystrophic and immune-deficient mice) before and after excision of floxed immortalizing sequences (by a non-integrating lentiviral vector). Engraftment, dystrophin production, amelioration of the pathology and functional recovery will be tested in transplanted mice. This project will set the stage for a definitive cell therapy of DMD.</gtr:technicalSummary><gtr:potentialImpactText>Although cardiovascular and neurological diseases remain the most widespread and disabling in the Western world, musculoskeletal impairments are among the most frequent causes of disability, encompassing more than 150 diseases and affecting every age and socioeconomic group. The classic example is muscular dystrophy, which can appear from infancy to adulthood and affects over 300,000 European citizens. This group of diseases alone poses serious social and economic problems for each national health system, considering the cost for repeated hospitalizations, home assistance, physiotherapy, surgery, medical devices for a devastating disease that takes now decades from diagnosis to death with a progressively deterioration of life quality.
Our project aims to demonstrate safety and efficacy for rapid clinical translation of this cell therapy strategy for Duchenne muscular dystrophy, though restricted to patients in a paediatric age and whose mutation cannot be treated by the simpler exon-skipping strategy. We aim to achieve a significant stabilization/amelioration of clinical symptoms. Importantly, even a partial effect would produce an enormous benefit for patients.
Together with patients, their families would benefit of the success of this project, not only in terms of emotional impact but also in practical terms, due to a reduction of the daily heavy burden related to continuous assistance to patients who are non ambulant and, later, totally unable to move.
The National Health Service would also indirectly benefit, not only for the implementation of available therapies, but also in economic terms. Although cell therapies are expensive and patient-tailored, they would still be cheaper that the total costs for the NHS, related to diagnosis, medical care, surgery, physiotherapy, drugs, medical devices that are required for decades.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>723336</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tottori University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Engineering and next generation HACs and their transfer to myogenic stem cells</gtr:description><gtr:id>746BC831-3408-4A5F-B351-394F24F4B5CB</gtr:id><gtr:impact>Outputs:
- New multigene plasmid containing MyoDER, dystrophin cDNAs and iCaspase9 successfully amplified
- New HAC containing the above plasmid
- Scientific interaction leading to a review manuscript just accepted for publication and to charity-funded PhD studentship starting in January 2015

Multidisciplinary collaboration: molecular biology, genetic engineering, cell biology, regenerative medicine.</gtr:impact><gtr:partnerContribution>Professor Oshimura and Dr Uno spent a sabbatical (3 months; June-September 2014) in the UCL Dept of Cell and Developmental Biology. They provided expert assistance and knowledge for the engineering and cloning of the two main plasmids containing the multi-genes that ultimately go inside the new HAC.
Dr Kazuki and Dr Hiratshuka from Tottori University also assisted in this collaboration.</gtr:partnerContribution><gtr:piContribution>Our research team was leading this collaboration. Dr Hoshiya was the main researcher interacting with the two collaborators and succeeded in obtaining the new construct leading to the next generation HAC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Disease modelling with iPS cells for congenital muscular dystrophies</gtr:description><gtr:id>A0FAB0E0-F68B-42EB-96E8-7F15CFF81DBE</gtr:id><gtr:impact>BBSCR funded PhD studentship</gtr:impact><gtr:partnerContribution>Prof Zammit and his group provides assistance in outcome measure (quantification of nuclear abnormalities) and oligonucleotides to screen.</gtr:partnerContribution><gtr:piContribution>Thanks to the networking opportunity offered by MR/J006785/1 funding, Dr Tedesco (co-investigator) established a fruitful collaboration with Prof Zammit to explore iPS cells for disease modelling of congenital muscular dystrophies (BBSRC funded, LiDO PhD studentship).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Medicine</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Department of Biomedical Science</gtr:department><gtr:description>Artificial Chromosomes for the therapy of muscular dystrophies</gtr:description><gtr:id>5FC7D484-F45E-4103-B9AC-F768CFCC82D9</gtr:id><gtr:impact>Tedesco et al. Science Translational Medicine 4:140ra89, 2012.
Tedesco et al. Science Translational Medicine 3:96ra78, 2011
Hoshiya et al. Mol Ther. 17:309-17, 2009.</gtr:impact><gtr:partnerContribution>Collaborators helped us to familiarize with chromosomal engineering and transfer.</gtr:partnerContribution><gtr:piContribution>We previously used first generation Human artificial Chromosome encoding the the dystrohin gene in the first pre-clinical protocol of cell therapy for Duchenne Musucular Dystrophy (Tedesco et al. Sci. Transl. Med. 2011).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Medicine</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Department of Biomedical Science</gtr:department><gtr:description>Artificial Chromosomes for cell therapy of muscular dystrophy</gtr:description><gtr:id>ED3BE685-99D1-4FD9-A4FE-57B5B2FE1E2E</gtr:id><gtr:impact>Three papers have been already published with this collaboration (Hoshiya H et al, Mol Ther 2009; Tedesco FS et al., Sci Transl Med 2011; Tedesco FS et al., Sci Transl Med 2012). The team is multidisciplinary: 
London: muscle regeneration, cell biology and HAC engineering.

Tottori: chromosome engineering.

Pavia: bioengineering.</gtr:impact><gtr:partnerContribution>Prof. Oshimura's group is contributing by reviewing the critical steps of cloning for the engineering of the new HAC. Dr Elvassore's group is testing by western blot dystrophin production in vitro in HAC-corrected cells.</gtr:partnerContribution><gtr:piContribution>We have strengthen our collaboration with the group of Prof. Mitsuo Oshimura (Tottori University). We are mainly engineering a new HAC and developing the platforms (in vitro and in vivo) to test its safety and efficacy once developed. Additionally, the group of Dr Elvassore is collaborating with us in order to test gene expression and protein production of DYS-HAC-corrected cells in vitro in combination with biomaterials to improve cell differentiation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pavia</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Faculty of Engineering</gtr:department><gtr:description>Artificial Chromosomes for cell therapy of muscular dystrophy</gtr:description><gtr:id>847774D3-51C9-41A0-B4E6-80192E07A023</gtr:id><gtr:impact>Three papers have been already published with this collaboration (Hoshiya H et al, Mol Ther 2009; Tedesco FS et al., Sci Transl Med 2011; Tedesco FS et al., Sci Transl Med 2012). The team is multidisciplinary: 
London: muscle regeneration, cell biology and HAC engineering.

Tottori: chromosome engineering.

Pavia: bioengineering.</gtr:impact><gtr:partnerContribution>Prof. Oshimura's group is contributing by reviewing the critical steps of cloning for the engineering of the new HAC. Dr Elvassore's group is testing by western blot dystrophin production in vitro in HAC-corrected cells.</gtr:partnerContribution><gtr:piContribution>We have strengthen our collaboration with the group of Prof. Mitsuo Oshimura (Tottori University). We are mainly engineering a new HAC and developing the platforms (in vitro and in vivo) to test its safety and efficacy once developed. Additionally, the group of Dr Elvassore is collaborating with us in order to test gene expression and protein production of DYS-HAC-corrected cells in vitro in combination with biomaterials to improve cell differentiation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference of patients affected by Duchenne Muscular Dystrophy and their families</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8D5A917E-EF9A-41E8-ACB7-A836737794E4</gtr:id><gtr:impact>XIII INTERNATIONAL CONFERENCE ON DUCHENNE AND BECKER MUSCULAR DYSTROPHY
21 - 22 February 2015, The Church Palace, Rome - Italy</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>492000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>EC FP7 Collaborative projects</gtr:department><gtr:description>PluriMes EC FP7 consortium</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>602423</gtr:fundingRef><gtr:id>8BC5B53D-9393-4618-9098-0F53816828E8</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>114326</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Muscular Dystrophy Campaign PhD Studentship</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:fundingRef>RA4/3023/1</gtr:fundingRef><gtr:id>055D448C-0E80-4F09-B981-F9F1CFF9C943</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>251998</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>New Frontier Science</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Takeda Pharmaceutical Company</gtr:fundingOrg><gtr:id>7B6C5556-4E2D-42F9-AAB9-AF3D3F0C7092</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studenship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A171E4B3-3C11-4C4D-B5FE-89C5D658580C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the derivation of mesoangioblast-like (MAB-like) cells from pluripotent cells such as induced pluripotent (IPS) and embryonic stem (ES) cells, to cells obtained thereby and to medical uses of such cells, in particular in the treatment of muscular dystrophies.</gtr:description><gtr:id>8456B2DE-E741-4A03-BD1E-6D9D50B3FAAA</gtr:id><gtr:impact>Industry-Academia collaboration with Takeda Pharmaceuticals funded via their New Frontier Science scheme.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013108039 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method for obtaining MAB-like cells and uses thereof</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Mesoangioblast-based gene therapy for Duchenne Muscular Dystrophy: a phase I/IIa study / DMD04 (DMD05)

Background

We pioneered cell therapy for muscular dystrophy with mesoangioblasts (MABS), vessel-associated myogenic progenitors, able to cross the endothelium when delivered intra-arterially and thus distribute evenly to dystrophic muscle. After satisfactorily testing the protocol in three mouse and one dog model of muscular dystrophy and toxicity studies, five DMD (age 8-12, two wheelchair-bound) were selected for a first-in-human, exploratory, prospective, non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor MABS transplantation (Eudract Number: 2011-000176-33). The trial proved safety but not efficacy, at variance with results obtained in pre-clinical models (Cossu et al. EMBO Mol. Med. 2015). Among relevant factors were the advanced age of patients and consequent low engraftment that should improve in younger patients. Even so, the level of engraftment will probably remain below the threshold of clinical efficacy. In order to approach and eventually reach clinical efficacy, several steps are being taken to implement the transplantation protocol. Among these, we moved to autologous cells, genetically corrected with a lentiviral vector expressing a small nuclear RNA (U7) engineered to recognize and skip exon 51. In other words this would be a cell-mediated exon skipping. Importantly, the snRNA from genetically corrected autologous cells should correct also neighboring nuclei, inside multinucleated fibers, and thus multiply the therapeutic effect. This novel protocol needs to be first tested locally for safety reasons and this will be done in this study.

Study design

The study will be a single centre, prospective, sequential, non-randomised, open-label clinical phase I-II study of cell-mediated gene therapy for DMD with autologous, genetically corrected human mesoangioblasts (auto-MABS). 
1. Mesoangioblasts will be isolated from a small foot muscle (EBD) of one non-ambulant patient, with a skippable mutation in exon 51, as a separate protocol (DMD05), necessary to validate the SOPs and prepare an IMPD to be submitted to MHRA. The cells will be transduced with a GMP lentiviral vector expressing a small nuclear RNA engineered to skip exon 51, thus restoring the dystrophin reading frame. Transduced cells will be tested for proliferation, differentiation, chromosome abnormalities, pro-vector insertion sites and tumour formation in SCID/bg mice.
2. This patient will be offered the possibility of participating in the subsequent trial (DMD04).
3. Four patients (+ the one of DMD05) will be recruited and undergo a biopsy (except Patient #1 who will have already done it). As in DMD05, cells will be transduced and characterised as in DMD05.
4. After successful completion of the pre-clinical work, cells will be injected into the contra-lateral EBD. After three months a biopsy of the injected muscle will analyse engraftment of transplanted cells and dystrophin production. 
5. If dystrophin accumulation is = 10% of a healthy muscle, cells will be subsequently injected in the muscles of the thumb, whose force of contraction will be measured. While safety will represent the primary outcome, increased force of the thumb might improve the quality of the patient's life.

Study Objectives:

1. Safety: To assess the incidence of adverse events (any grade) in DMD patients treated with intra-muscular (foot and hand) injections of auto-MABS after genetic correction with a lentiviral vector expressing a small nuclear RNA engineered to skip exon 51 of the dystrophin gene.
2. Efficacy: A) To determine the effect of a single intra-muscular injection into the foot EBD of genetically corrected auto-MABS in inducing cell engraftment and dystrophin synthesis. B) To determine the ability of genetically corrected auto-MABS to increase the force of contraction of the thumb after single intra-muscular injections in the Adductor pollicis, Opponens pollicis, Abductor pollicis brevis and Flexor pollicis brevis of the dominant hand.

Contributors:

1. University of Manchester, Institute of Inflammation and Repair: study coordination. G. Cossu (PI), pre-clinical work and analysis of biopsies (QT-PCR). Urmaas Rostalu, Francesco Galli, Bashar Aldeiri, Laricia Braggs, Alessandra Albertini (team).
2. Royal Manchester Children Hospital and NIHR / Wellcome Trust Manchester Clinical Research: Clinical work. Patient selection, treatment and follow up. Analysis of clinical endpoints. Imelda Hughes (Clinical Chief Investigaror) and Gary McCullagh. 
3. Institute of Child Health, UCL: Study design, Analysis of biopsies (IF and WB) expertise in muscle cell biology. Francesco Muntoni, Silvia Torelli, Jennifer Morgan 
4. University of Manchester, Cleanrooms, Core Technology Facility: isolation, expansion and characterization of MABS as Investigational Medicinal Product. Sue Kimber and Joan Benson.
5. GMP facility at the Denmark Hill campus, KCL. GMP Lentiviral production. Farzin Farzaneh, and Rebecca Prue.
6. The Cell Therapy Catapult. Regulatory aspects. Jacqueline Barry.
7. UMIP (University of Manchester Intellectual Property), Commercialization. Arnaud Gar&amp;ccedil;on.</gtr:description><gtr:id>12425C44-A9F1-467C-8B67-DD9656F0C410</gtr:id><gtr:impact>The trial will have as first end point dystrophin production. If after cell injection, we will be able to measure an amount of dystrophin which is 10% or more of a healthy muscle, we will inject other cells, similarly corrected in the thumb of the same patient. An increase of force of contraction would greatly benefit the quality of every day life in patients. Moreover this outcome would set the basis for a subsequent trial, this time in very young patients with systemic distribution and a defined &amp;quot;intent to cure&amp;quot;</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Mesoangioblast-mediated exon skipping for genetic correction of exon 51 mutation, based upon a single injection in individual skeletal muscles of five non ambulant patients affected by Duchenne Muscular Dystrophy: a non randomized, open label, phase I/IIa study.</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:ukcrnIsctnId>N/A</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a new method that allows adhesion of chicken DT40 cells (normally growing in suspension) for direct production of microcells.</gtr:description><gtr:id>68C772E6-C8D6-402B-BC0B-4353204E12D4</gtr:id><gtr:impact>Microcells could be then directly used to target cells for HAC transfer. This method significantly accelerate HAC transfer, avoiding the intermediate step of transfer into Chinese Hamster Ovary cells.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A novel method for direct microcell production for HAC transfer from DT40 cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed a new Dys-HAC, named 13, containing a inducible Caspase9, followed by an inducible human MyoD-ER and codon-optimised human dystrophin cDNA, driven by SPC5-12 (a synthetic potent muscle specific promoter), and multi integrate and mutated p-lox sites.</gtr:description><gtr:id>FB24BD32-A161-4A53-B9E9-42C99B9FC7B9</gtr:id><gtr:impact>This new construct will allow the derived human cell line, to undergo robust muscle differentiation at our will (MyoD-ER), to be susceptible to induced apoptosis (as a safety devise through i-Caspase 9) and to over produce dystropin.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Construction of a new Dys-HAC-13</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new intermediate HAC has been developed after removal of HSTK and GFP that are strongly immunogenic. In addition, resistance genes (also potentially immunogenic but needed for selection) have been floxed so that they can be excised when needed</gtr:description><gtr:id>D9E846EB-11FC-4EAA-8DCE-E37B541F08BE</gtr:id><gtr:impact>The new vectors will be instrumental towards the building of the final HAC, aim of this project.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A novel DYS-HAC, devoid of immunogenic proteins (e-GFP and HSTK) with floxed resistance genes</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A tamoxifen inducible MyoD was inserted inside the new HAC in order to induce muscle differentiation upon tamoxifen administration.</gtr:description><gtr:id>B50691B3-551D-4804-8755-F0A9499EC88D</gtr:id><gtr:impact>It is expected that this reagent will facilitate muscle differentiation of cells harboring the novel HAC</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A new HAC containing an inducible MyoD (MyoD-ER)</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have constructed a new Dys-HAC containing Blasticidin gene, EGFP and an immortalising cassette (Bmi-1, Telomerase and HSTK suicide gene) and finally an inducible Cre-ERT2 gene that may allow to remove this flexed cassette from the HAC upon Ganciclovir treatment. The two constructs (14 and 15) differ for the location and method of integration into the HAC.</gtr:description><gtr:id>2B8CF661-35C8-4D0F-B18A-80E513C8CDD4</gtr:id><gtr:impact>These novel constructs, ready to be transferred into human cells will allow the induction of unlimited proliferation (thanks to Bmi-1 and Telomerase) and at the same time, excision of the function when differentiation or transplantation will be required. Since Cre mediated excision is never 100% efficient we also have an inducible suicide gene (HSTK) which allows to selectively kill those cells (10% in preliminary experiments) where the cassette is not excised. Remarkably, human cells, with the same active cassette (though in a different molecular context) are not tumorigenic in immune deficient mice.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Construction of a new Dys-HAC-14 and 15</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Microcell-mediated chromosome transfer (MMCT) is a method that enables the transfer of chromosomes from donor to recipient cells. It involves fusion of microcells (small particles of nuclear and plasma membrane containing one or a few chromosomes) with cells, and the following selection of cell hybrids. MMCT can be used to study in-vitro, or in-vivo outcomes of the transferred chromosome with a range of cell lines. We have developed a method to overcome current obstacles that are limiting MMCT utilisation. This protocol results in a cost-effective microcell manufacturing procedure that is amenable to scale-up and diffuse microcell-based technologies such as HAC-transfer for gene therapy.</gtr:description><gtr:id>EA3FA520-7ED0-4016-B2FD-C0CD1C37472A</gtr:id><gtr:impact>We obtained a decrease in cost and time complemented by a significant increase in the number of microcells extracted, eliminating the requirement of a super-centrifuge machine, setting the basis to scale-up microcell production for chromosome transfer.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A Highly Efficient Method of Microcell Production for Chromosome Transfer</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have almost completed the designing of the final sequence of a novel multifunctional DYS-HAC. This includes a number of genes regulating proliferation, differentiation and safety of the construct. Those genes are assembled into two large DNA vectors and we will be sending them very shortly for gene-synthesis. Afterwards we will modify our current HAC backbone by inserting those sequences by chromosome engineering. As a proof of principle for our approach, we have successfully synthesized and</gtr:description><gtr:id>49F24C16-1AEC-47F1-A935-CD8CC7F61B09</gtr:id><gtr:impact>The development of this material is critical for the successful development of the project since it constitutes one of the main parts to engineer the novel HAC. Notably, this will be the first evindece of gene-synthesis mediated chromosomal engineering. If successful this technique will significantly impact on the chromosomal engineering community providing a way to facilitate what is usually a time consuming and technically challenging process.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Novel DYS-HAC sequence (and human MyoD-ER plasmid)</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have succeeded in obtaining 8 different clones of lentiviral reversibly immortalised mesoangioblasts from Duchenne patients containing a novel DYS-HAC (DYS-HAC2) with reduced immunogenic potential.</gtr:description><gtr:id>E5416281-3A28-4594-9E39-64405B9147ED</gtr:id><gtr:impact>This is the first evidence of HAC transfer in clinically relevant cell types. Transplantation studies showed engraftment in dystrophic mice and the same method is currently being applied to transfer DYS-HAC2 also to human myoblasts.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Human dystrophic (DMD) reversibly immortalized mesoangioblasts containing DYS-HAC2</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A10EBF1C-58B2-4D18-8FD9-59854DA582B6"><gtr:id>A10EBF1C-58B2-4D18-8FD9-59854DA582B6</gtr:id><gtr:title>Pericytes in development and pathology of skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fae8d7e266f179c0d9d26bcf9ebf219"><gtr:id>3fae8d7e266f179c0d9d26bcf9ebf219</gtr:id><gtr:otherNames>Cappellari O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C2E066D-55A6-40E0-BB54-AA4E009F1CC1"><gtr:id>5C2E066D-55A6-40E0-BB54-AA4E009F1CC1</gtr:id><gtr:title>Handbook of Stem Cells</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1b8210c402ce98d879641b81f050086"><gtr:id>f1b8210c402ce98d879641b81f050086</gtr:id><gtr:otherNames>Tedesco, FS, Sampaolesi, M and Cossu, G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-0-12-385942-6</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA79471F-E28F-4B78-ACCF-4087C376F85B"><gtr:id>AA79471F-E28F-4B78-ACCF-4087C376F85B</gtr:id><gtr:title>Dll4 and PDGF-BB convert committed skeletal myoblasts to pericytes without erasing their myogenic memory.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3fae8d7e266f179c0d9d26bcf9ebf219"><gtr:id>3fae8d7e266f179c0d9d26bcf9ebf219</gtr:id><gtr:otherNames>Cappellari O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89F898C9-B6E4-4FD5-BE21-2487347CFF10"><gtr:id>89F898C9-B6E4-4FD5-BE21-2487347CFF10</gtr:id><gtr:title>Targeting endothelial junctional adhesion molecule-A/ EPAC/ Rap-1 axis as a novel strategy to increase stem cell engraftment in dystrophic muscles.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/189595a4f6ee62f701a911031c0fdadb"><gtr:id>189595a4f6ee62f701a911031c0fdadb</gtr:id><gtr:otherNames>Giannotta M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CBECF974-4D47-4AC5-B46B-4304AA573416"><gtr:id>CBECF974-4D47-4AC5-B46B-4304AA573416</gtr:id><gtr:title>Muscle Interstitial Cells: A Brief Field Guide to Non-satellite Cell Populations in Skeletal Muscle.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ded1be63d0277e5d3e5e2f389db3bc6f"><gtr:id>ded1be63d0277e5d3e5e2f389db3bc6f</gtr:id><gtr:otherNames>Tedesco FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1D5ECF8-7BA8-438F-AF7D-0D90AF0FA1E7"><gtr:id>D1D5ECF8-7BA8-438F-AF7D-0D90AF0FA1E7</gtr:id><gtr:title>Out of the niche: exploring unknown pathways.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07ff9e46979281ecf2318da76fbce852"><gtr:id>07ff9e46979281ecf2318da76fbce852</gtr:id><gtr:otherNames>Moore K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09F5B5C6-6B0A-4A08-B9D7-79AE1BDF1561"><gtr:id>09F5B5C6-6B0A-4A08-B9D7-79AE1BDF1561</gtr:id><gtr:title>Reversible immortalisation, human artificial chromosomes, and induced pluripotency: new gene and cell therapy technologies for Duchenne muscular dystrophy</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f777c13410abce484f877a4fb37829ab"><gtr:id>f777c13410abce484f877a4fb37829ab</gtr:id><gtr:otherNames>Benedetti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/914024F6-15D6-4C5A-8B5D-132E4CFDD42C"><gtr:id>914024F6-15D6-4C5A-8B5D-132E4CFDD42C</gtr:id><gtr:title>In vivo generation of a mature and functional artificial skeletal muscle.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3188bfb33646ac4345a1d794ea628bf4"><gtr:id>3188bfb33646ac4345a1d794ea628bf4</gtr:id><gtr:otherNames>Fuoco C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B92415B-E72F-45A3-A0D7-4ACE378831A1"><gtr:id>9B92415B-E72F-45A3-A0D7-4ACE378831A1</gtr:id><gtr:title>Reversible immortalization allows human artificial chromosome-mediated gene correction of human dystrophic muscle progenitor cells</gtr:title><gtr:parentPublicationTitle>Neuromuscular Disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f777c13410abce484f877a4fb37829ab"><gtr:id>f777c13410abce484f877a4fb37829ab</gtr:id><gtr:otherNames>Benedetti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BC3B280-44D8-4847-99FD-0152905980DF"><gtr:id>2BC3B280-44D8-4847-99FD-0152905980DF</gtr:id><gtr:title>Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f777c13410abce484f877a4fb37829ab"><gtr:id>f777c13410abce484f877a4fb37829ab</gtr:id><gtr:otherNames>Benedetti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E41ED1BF-97D3-4898-ABE4-15FB89C8F8D9"><gtr:id>E41ED1BF-97D3-4898-ABE4-15FB89C8F8D9</gtr:id><gtr:title>Essentials of Stem Cell Biology</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0074b6d69b2b6902ccf093d2e36d78f4"><gtr:id>0074b6d69b2b6902ccf093d2e36d78f4</gtr:id><gtr:otherNames>Tedesco F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780124095038</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A3DC4DB3-432F-4D92-B9B3-E5A4FEAB2F05"><gtr:id>A3DC4DB3-432F-4D92-B9B3-E5A4FEAB2F05</gtr:id><gtr:title>Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes.</gtr:title><gtr:parentPublicationTitle>Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ded1be63d0277e5d3e5e2f389db3bc6f"><gtr:id>ded1be63d0277e5d3e5e2f389db3bc6f</gtr:id><gtr:otherNames>Tedesco FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0967-3849</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1DDC1DB-323C-4EED-AD67-60D626594DAD"><gtr:id>F1DDC1DB-323C-4EED-AD67-60D626594DAD</gtr:id><gtr:title>Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ecb862fe535d75b36be733c8b48c8a3"><gtr:id>3ecb862fe535d75b36be733c8b48c8a3</gtr:id><gtr:otherNames>Cossu G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DDB66BAC-EE6D-43A4-9FBA-4AB6CC861D05"><gtr:id>DDB66BAC-EE6D-43A4-9FBA-4AB6CC861D05</gtr:id><gtr:title>Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration.</gtr:title><gtr:parentPublicationTitle>Skeletal muscle</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3188bfb33646ac4345a1d794ea628bf4"><gtr:id>3188bfb33646ac4345a1d794ea628bf4</gtr:id><gtr:otherNames>Fuoco C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2044-5040</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C87AB71-9967-4AB1-AC56-7448BD80C3A9"><gtr:id>8C87AB71-9967-4AB1-AC56-7448BD80C3A9</gtr:id><gtr:title>Human Artificial Chromosomes and iPS cells for ex vivo gene therapy of muscular dystrophies and beyond. Journal of Neuromuscular Diseases, 2014 1 S3-S79.</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ded1be63d0277e5d3e5e2f389db3bc6f"><gtr:id>ded1be63d0277e5d3e5e2f389db3bc6f</gtr:id><gtr:otherNames>Tedesco FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0928C216-62B1-49C9-A28B-A06A5DFA43E2"><gtr:id>0928C216-62B1-49C9-A28B-A06A5DFA43E2</gtr:id><gtr:title>iPS cells and human artificial chromosomes: towards a genomic integration-free therapy for Duchenne muscular dystrophy</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4fe55913b52f44fbb086d53d727a54a1"><gtr:id>4fe55913b52f44fbb086d53d727a54a1</gtr:id><gtr:otherNames>Ferrari G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62624DBF-226A-44BC-A569-361E3466B4E3"><gtr:id>62624DBF-226A-44BC-A569-361E3466B4E3</gtr:id><gtr:title>Stem cell therapies for muscle disorders.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ded1be63d0277e5d3e5e2f389db3bc6f"><gtr:id>ded1be63d0277e5d3e5e2f389db3bc6f</gtr:id><gtr:otherNames>Tedesco FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFF168E9-F72B-44C9-BE59-DFBB42B16EA9"><gtr:id>FFF168E9-F72B-44C9-BE59-DFBB42B16EA9</gtr:id><gtr:title>P66 iPS cells and human artificial chromosomes: novel therapeutic tools for muscle disorders</gtr:title><gtr:parentPublicationTitle>Neuromuscular Disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0074b6d69b2b6902ccf093d2e36d78f4"><gtr:id>0074b6d69b2b6902ccf093d2e36d78f4</gtr:id><gtr:otherNames>Tedesco F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F3520E6-BEEE-4EBE-9459-F372B6E35934"><gtr:id>0F3520E6-BEEE-4EBE-9459-F372B6E35934</gtr:id><gtr:title>Collagen VI regulates satellite cell self-renewal and muscle regeneration.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f195ba155a3cf0f1e709391a0a676add"><gtr:id>f195ba155a3cf0f1e709391a0a676add</gtr:id><gtr:otherNames>Urciuolo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D650FA12-E7A2-4177-BD5E-FD281A1B1B64"><gtr:id>D650FA12-E7A2-4177-BD5E-FD281A1B1B64</gtr:id><gtr:title>Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes.</gtr:title><gtr:parentPublicationTitle>Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ded1be63d0277e5d3e5e2f389db3bc6f"><gtr:id>ded1be63d0277e5d3e5e2f389db3bc6f</gtr:id><gtr:otherNames>Tedesco FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0967-3849</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A30215B-947C-4EF0-B252-8E467241DA38"><gtr:id>6A30215B-947C-4EF0-B252-8E467241DA38</gtr:id><gtr:title>Handbook of Stem Cells</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0074b6d69b2b6902ccf093d2e36d78f4"><gtr:id>0074b6d69b2b6902ccf093d2e36d78f4</gtr:id><gtr:otherNames>Tedesco F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>9780123859426</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E48C9EC-758A-4F37-A6A8-1F26F5AE16F9"><gtr:id>3E48C9EC-758A-4F37-A6A8-1F26F5AE16F9</gtr:id><gtr:title>PW1/Peg3 expression regulates key properties that determine mesoangioblast stem cell competence.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42ad45c5b2da192fcbc681fc56a5059f"><gtr:id>42ad45c5b2da192fcbc681fc56a5059f</gtr:id><gtr:otherNames>Bonfanti C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A60961B3-44CC-43FB-B42A-2021E12DF930"><gtr:id>A60961B3-44CC-43FB-B42A-2021E12DF930</gtr:id><gtr:title>Stem cell transplantation for muscular dystrophy: the challenge of immune response.</gtr:title><gtr:parentPublicationTitle>BioMed research international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8256fcc223ee5134647276670b7cbd6"><gtr:id>f8256fcc223ee5134647276670b7cbd6</gtr:id><gtr:otherNames>Maffioletti SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/283AC303-6476-4286-9EFF-76B141E38905"><gtr:id>283AC303-6476-4286-9EFF-76B141E38905</gtr:id><gtr:title>Human artificial chromosome-mediated strategies for stem cell-based therapy of muscular dystrophy</gtr:title><gtr:parentPublicationTitle>CHROMOSOME RESEARCH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ffc294dd5d3d2f0dfdf1985d46c046e"><gtr:id>5ffc294dd5d3d2f0dfdf1985d46c046e</gtr:id><gtr:otherNames>Hoshiya H.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0967-3849</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B18AD658-7487-4B2D-B997-D2B3EA5D4CC3"><gtr:id>B18AD658-7487-4B2D-B997-D2B3EA5D4CC3</gtr:id><gtr:title>Transplantation of induced pluripotent stem cell-derived mesoangioblast-like myogenic progenitors in mouse models of muscle regeneration.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4810a0cf76775c4651e12adef68b26fe"><gtr:id>4810a0cf76775c4651e12adef68b26fe</gtr:id><gtr:otherNames>Gerli MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E2061A4-3BC5-4225-B63A-2FB8DC51C3B1"><gtr:id>0E2061A4-3BC5-4225-B63A-2FB8DC51C3B1</gtr:id><gtr:title>Human artificial chromosome-mediated genetic correction of human dystrophic skeletal muscle progenitors for the autologous cell therapy of Duchenne muscular dystrophy</gtr:title><gtr:parentPublicationTitle>HUMAN GENE THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b4d044c8e1857ec884440e9073a0aca2"><gtr:id>b4d044c8e1857ec884440e9073a0aca2</gtr:id><gtr:otherNames>Benedetti S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J006785/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>